

10/507409





2/24 SUBSTITUTE SHEET (RULE 26)

6240.0 9140.0 10730.0 21350.0 20580.0 7000.0 9700.0 11030.0 20700.0 19150.0 70m0 15m0 15m0 15m0 7500 10m0 37200.0 80460.0 245100.0 213760.0 \$4,385,400,00 \$6,250,000,00 \$864,200,00 7020 1700.0 1700.0 1700.0 100.0 100.0 100.0 \$6,432,500.00 15,052,443,25 8480,036.75 888 8885 8 8 8 8 Figure 2A - Details for Attributing Variances to a Product within a Product Mix 450 2550 21750 081 081 081 082 082 082 3 3 5 5 5 22 to \$571,500.00 , § 3 8 8 22.02 20.202 20.202 20.202 20.202 0051 0008 0057 5 5 3 8 8 8 14000 1127 1228 1427 \$1,639,050.00 Matrix Algebra Application to Accounting Cost Variance Analysis Product Dimension 10450 19470 61990 54860 0 44 666 666 0 E 8 8 8 8 8 8 8 8 8 8 8 2 2 2 3 ABM-RCP Variance Analytics Model PCT Patent Submission - 2003-03-13 Budgetad Prices, Activities, Volumes and Costs Actual Prices, Activities, Volumes and Costs Colin M. Lay and Ron Eden University of Ottawa 2003-03-11 02:13 PM

Figure 28 - Cost Variance Components for Products


ABM-RCP Variance Analytics Model
PCT Patent Submission - 2003-03-13
Coloral Layard Ren Edm
University of Ozeana
2003-03-11 08-28 PM


ī							
70 50	100	l		۱	ı		
Product Dimension	DE CONTRACTOR OF THE CONTRACTO		Cancerdone	Central Jung	J	Heart Disease	
Cost Variance Answers	1	****	l	DKO.	ORGS	DRG8	Total
ACING Total Costs	41 124 AKK CD	61 640 441 65	200 000 000	***************************************		-	
Budoethe Total Cost	_		000000000000000000000000000000000000000	de la constant	30.100	CO Vote Sans	F. 102 45.73
Total Cody land	_	200		ASI 1, BOAL US	CO TOPE TOPE	00 D00,000,00	200000
	2244 (03.17)	1200,163,50	57,886,23	278,120,00	23 504 60	(\$3),068,00)	\$500,000,25
Mein Cost Variables Consults							
a to south and south and							
a (d) extense and a suprement of sections of	3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3		2009/74	218,562,50	27,52,60		27 25 20
No source Conversion Endantly Value (K)		•		113,425,00	888	•	6134,695,00
		(87,000,00)	(22 400 00)	221,500,00	(\$2,670.00)	\$45,600,00	2155.180.00
Patent Mx Varience (m) =	\$107,600.00	\$221,800,00	20.00	(\$38,100,00)	8	2	BR2 700 00
Total of Main Components	•						
Interaction Variance Companies							
SUDDELINIUM AND							
Renounce Price, Efficiency (p.R.) *	25 000 X	\$22£80	\$882.50	\$1,368,75	(1973.00)	(\$1.178.0m)	27 600 25
Resource Price, Utilization (p.U.) *	888	(\$582.50)	(\$30.00)	\$1,406.25	(S) 182 SD	53 200 m	2 30 2
Resource Price, Pedent Mix (p.m) s	*	88.980.00	8	CH 212 40	8	100 000	
Efformer, Utilization (P.U) =	-	\$1 000.00	AND ROLL	2 5 5		(manage)	20707
Filled Contact District Contact Life All and an	_		(2)	The same	STATE OF THE PERSON NAMED IN	BOTE / 23	8 7 7 7
בייייייייייייייייייייייייייייייייייייי		\$2,080,00	**************************************	(\$883.00)	88	(\$14,380,00)	(M1, 185, 00)
· (M,C) when Patent Mix (U,m) ·	23,200,00	(\$1,020,00)	888	(\$2,100,00)	1000	(\$17.120.00)	(\$14,940,00)
Three Way Interactions							
Retriebe Dire Sintende Inthritos to Bills a	_						
- (a) Colored	•	00414	\$48.75	97.75	(90,736)	(6972828)	\$1,454.75
reactive Fried, Emourcy, Patient Mix (p.P.m.)	_	3300		(39.25)	80.08	\$225.00	\$573.75
Resource Price, Unitation, Patient Mix (p.U.m) .		(\$75.00)	-	(\$50.75)	900	(\$840.00)	C\$783,753
Emiliancy, University, Patent Mix (R.U.m) =	81.940.00	11400	\$0.00¢	(\$280,00)	2000	(\$546.00)	\$1,248.00
Four Way Interaction							
Resource Price, Efficiency, Utilization, Patient Libr (b. H. J.) =	2460	\$	\$				
				194490	· ·	007/88	2012
Total of Cost Variance Components	1248,655,00	\$290,143,50	821.988.25	128 120 00	828 ROA RO	W 196 UM	20 070 070


10/507409


Figure 2C - Revenue, Profit and Cost Variance Graphs at the Level of Patient Type

ABIM-RCP Variance Analytics Model
PCT Patent Submission - 2003-03-13
Caby M. Ly and Ron Eden
University of Ottawas
Totacocks 1 0413 PM









6/24

ABM-RCP Variance Analytics Model
PCT Patent Submission - 2003-03-13
Cells M. Lay and Ren Eden
University of Others
2003-00-11 (01.19 pu

Figure 25 - Cost Variance Analysis Results at Level of Product

Kon Eden						
teve						
11 OE:13 PM	Product-Group Dimension	Birms	Cancers	Heart Disease PGZ	Totale	
	Cost Variance Analysis	21 775 708 60	81.666.710.75	00 700 886\$	15 852 443 25	
	Budgesed Total Cost #	\$2,737,000,00	\$1,807,800,00	81,041,000.00	83,345,800,00	
	Total Cost Variance	\$538,708,60	\$78,910.75	(\$51,066,00)	\$560,643,25	
	Main Cost Variance Components		•			
	Resource Price Variance (p) =	\$84,125.00	\$80,637.50	\$24,500.00		
	Resource Conversion Efficiency Variance (R) =	\$33,600.00	\$29,195,00	\$77,800.00		
	Activity Utilization Variance (U) =	944,350,00	\$24,230,00	\$85,600,00	\$164,180.00	
	Patent Mtx Variance (m) =	\$329,000,00	(\$38,100.00)	(\$208,200,00)	\$52,700,00	
	Total of Main Components					
	Interaction Variance Components					
	Two way interactions					
	Resource Price, Efficiency (p.R) a	#22400	\$1,550.25	(\$1,175.00)	\$4,808,25	
	Resource Price, Utilization (p.U) *	(\$312.50)	\$163.75	22,200,00	52,189,23	
	Resource Price, Patient Mix (p,m) =	M0,150,00	(81,237.50)	(\$8,900.00)	\$20260	
	Efficiency, Uffizzation (R.U) =	\$20,480.00	\$5,379.00	\$2,730.00	\$25,589,00	
	Eficiency, Pasent Mix (R.m) *	53,880.00	(\$885.00)	(314,380,00)	(\$11,395,00)	
	Utilizaton, Palent Mix (U,m) *	\$4,250.00	(\$2,100,00)	(\$17,120,00)	(\$14,940,00)	
	Three Way Interactions				•	
	Resource Price, Efficiency, Utilization (p.R.U) = 1	\$1,415.00	1379.25	(\$337.50)	\$1,450.75	
	Resource Price, Efficiency, Petent Mix (p.R.m) =	\$430.00	(\$4.25)	\$235.00	57.72	
	Resource Price, Utilization, Patient Mix (p.U.m) =	(350.00)	(\$93.75)	_	(\$780,75)	
	Efficiency, Utilizaton, Patient Mix (R,U,m) =	\$2,094,00	(\$290,00)	(\$548.00)	\$1,248.00	
	Four Way Interaction		***		1	
Resource	resource Fince, Emdency, Usuzaton, Pasent Mix (p.K.U.m) =	N4KW	(322.50)	A5'70€	VO. TOTA	
		_				

ABM-RCP Variance Analytics Model Figure 3A - Details for Attributing Variances to

Colin M. Lay and Ron Edan	PCT Patent Submission - 2003-03-13	
	olin M. Lay and Ron Edan	

dagumb	₹	2	2	ŧ	2	Total
ř	0.000,7	٥	þ	P	F	7000.0
8	•	9,700.0		0	~	9700.0
\$	•	•	11,050.0	۰	-	11050.0
3	•	•	•	20,700.0	•	20700
2	ó	0	٥	0	19,150.0	19150
Rolegumb		•				
×	7,000,0	B	11,050.0	P.S	19,150.0	37200.0
2	8	10,400.0	11,050.0	20,700.0	38,300.0	89450.0
£	14,000.0	19,400.0	33,150.0	82,600.0	85,750.0	245100.0
ž	21,000.0	9,700.0	22,100.0	103,500,0	57,450.D	213750.0
pRdiagumb						
	\$371,000.00	2494,700,00	\$751,400.00	\$1,738,800,00	\$2,028,900,00	\$5,385,800,00

100	Marship 1	Numbo 2 .	Lab Tests	X-Rays	Pharmacy	,
	-	Ž	2	į	2	
₹	0.240.0	•	•	•	0	6240.0
থ	•	9,140.0	•	•	-	P140.0
3	•	•	10,750.0	•	•	10750.0
₹		•	•	21,350.0	•	21350.0
খ	٥	0	0	•	20,580.0	20550.0
gUma						
æ	0,064.0	0.0	12,900.0	4,270.0	18.5220	44754.0
22	4,120.0	17,366.0	8,600.0	12,025.0	24.988.0	97007.0
æ	20,600.0	13,710.0	40,850,0	87.535.0	92.610.0	255305.0
¥	32,980.0	7,3120	18,126.0	111,020.0	57.624.0	225041.0
IngUma						
	1810,172,00	1433,893.00	\$768,893,76	12,140,337,50	1 00 717 00 18	\$5,952,449,25

10/507409

ABM-RCP Variance Analytics Model Figure 38 - Supplementary matrix products for the activity level PCT Patent Submission - 2003-03-13

Cells M. Ly and Rea Eau University of Ottawa 2003-03-13

Cells M. Ly and Rea Eau University of Ottawa 2003-03-13

Social M. Ly and Rea Eau University of Ottawa 2003-03-13


Social M. Ly and Rea Eau University of Ottawa 2003-03-13


Additional Social M. Additional M. Additiona


Figure 3C - Cost Variance Components for Activities


ABM-RCP Variance Analytics Model
PCT Patent Submission - 2003-03-13
Colin M. Lty and Ren Eden
University of Carre


2003-03-11 08-13 PM	Z	2 Buysany	CONT CELL	XARays	Pharmacy	
y and Activity-Producing Department Dimension	W	W	ี	¥	2	Tota
Cost variance Anarysis						
Actual Total Cost =	\$610,172.00	\$433,693,00	\$766,693,75	\$2 140,337.50	\$1,898,347,00	15 952 443 25
Budgaled Total Cost =	837,000,00	\$494,700.00	8751,400,00	81.738.800.00	82,029,900,00	\$5.255,800,00
Total Cost Variance .	\$239,172,00	(\$81,007,00)	\$17,493,78	8401,637,50	(\$30,553,00)	\$566,643,25
· ·						
Main Cost Variance Components	-					
	51,750,00	\$30,375.00	811,050,00	877,625,00	\$52,602,50	\$178,482.50
Resource Conversion Endercy Varieties (K) =	1135,600,00	(359, BAD 00)	243,095,00	\$240,120,00	(\$214,480.00)	27,694.00
ACTIVITY UNITERIOR VEHICLES (U)	- 100,000,00	\$5,150.90	\$30,600.00	\$31,500,00	919,080,00	\$155,180,00
Patent Mix Variance (m)	(\$5,300,00)	(\$25,500,00)	(\$44,200.00)	\$25,200,00	\$132,500,00	\$82,700,00
Total of Math Components						
· Interaction Variance Components						
Two way interactions					•	
Resource Price, Efficiency to R) a	\$9,800.00	(\$970.00)	(815 100 75)	£18 630 00.	(47 640 00)	- FA ACM 25
Resource Price, Utilization (p.U) =	\$325.00	2375.00	8450.00	\$1.406.25	\$495 CD	\$2 150 83
Resource Price, Patient Mix (p,m) a	(\$25.00)	(\$1,875,00)	(\$650,00)	\$1.125.00	87.55	22012.50
Effdency, Utilization (R.U.)	\$25,220,00	(\$720,00)	31,755.00	\$4,350,00	(\$2.018.00)	628,689,00
Effdency, Patent Mix (R,m) a	(\$1,940.00)	\$3,600.00	(\$2,535,00)	23,480,00	(314,000,00)	(\$11,395.00
Utilizaton, Patent Mix (U,m) .	\$2,120.00	(\$8,160,00)	(\$6,800,00)	(\$2,100,00)	8	(\$14,940.00
The Way I was						
and day askertill i proceeding and aminosale	200	100 0101		44 554	100	1
Designation of the Company, Company of the Company	31,022,00	(310.00)	(\$616.75)	06'/25	(2/2/00)	51,456.75
Resource Fince, Emodercy, Pabent Mix (p, K,m) a	(\$140.00)	82000	\$802.75	\$270.00	(\$500.00)	1572.75
Kesource-Prog, United of Passell Max (p.U.m)	210.00	(3600.00)	(\$100,00)	(\$92.75)	8	(763.75
Efficiency, Utilization, Padent Mix (R.U.m) =	\$770.00	\$1,152,00	(\$390.00)	(\$290,00)	88	\$1,248,00
Four Way Interaction						
Resource Price, Efficiency, Utilizaton, Pafent Mix (p.R.U,m) =	\$58.00	19	137.5	-22.6	٥	\$187,00
Total of Control of State of S	0000					














ure 4A • Details for Attributing Variances to Individual Resource

ABM-RCP Variance Analytics Model PCT patent Submission - 2003-03-13 Colin M. Lay and Ron Eden University of Ottawa 2003-03-11 00:13 PM









13/24


BM-RCP Variance Analytics Model


	٠	
•	:	Resource s
3-03-13		

y and Ron Edan					
of Ottews		Reso	9 tourn		
2003-03-11 02-13 PM Resource Acquisition Dimension	Rt Rt	Lebour 2 R2	2 Supplies 1 R3	Supplies 2 R4	180
Cost Variance Analysis	83	81,456,455,00	\$2 170 082 50	\$1.744.067.78	15 000 441 75
Budgeted Total Cost a	\$520,800,00	\$1,162,830,00	\$2,205,800,00	\$1,496,250,00	13,165,600,00
Total Cost Variance a	\$61,028,00	\$293,605,00	(\$35,607,50)	\$247,817,79	\$566,643,25
Main Cost Variance Components					
Resource Price Variance (b) =	(\$37,200.00)	\$178,900.00	(\$122,550,00)	\$180,312.50	\$179,462.50
Resource Conversion (Efficiency Variance (R) in Action Littlesfor Variance (I) in	\$71,890.00	\$64,028.00	(3138.00)	(\$1,085,00)	\$134,604.00
Patent Mix Variance (m) =	\$7,000,00	\$14,950.00	\$38,700,00	\$22,050,00	\$62,700.00
Total of Math Components					
Interaction Variance Components					
Two way interactions					
Resource Price, Efficiency (p.R) =	(\$5,135.00)	\$9,850.00	\$7.60	(\$116.25)	14,000,25
Resource Price, Utilization (p.U) =	(\$1,630.00)	\$2,770,00	· (\$3,275.00)	\$5,460,25	13,031.23
Resource Price, Patent Mix (p.m) *	(\$500.00)	\$2,300.00	(\$2,150.00)	\$2,362.50	12,012.50
Efficiency, Utilization (R.U) =	00 RJ 878 00	\$3,685.50	\$8,167.50	\$7,658.00	\$28,588,00
Efficiency, Patent Mix (R,m) =	(82,670,00)	(\$1,235.00)	(\$8,235.00)	\$945.00	(\$11,398.00)
Utilization, Patient Mix (U.m) =	(\$840.00)	(\$5,785.00)	(\$5,780,00)	(\$2,555,00)	(\$14,040,00)
Three Way interactions					
Resource Price, Efficiency, Utilization (p.R.U) =	(\$277.00)	\$1,367.00	(\$453.75)	\$820.50	\$1.450.75
Resource Price, Efficiency, Patient Mix (p.R.m) =	\$206.00	(8190.00)	\$467.50	\$101.25	\$57.8.75
Resource Price, Uffizzaton, Patient Mix (A.U.m) e	\$50.00	(\$890.00)	\$320.00	(\$272.75)	(\$789,75)
Efficiency, Utilizaton, Patent Mix (R.U.m) =	(\$294,00)	\$565.50	\$157.50	\$619.00	\$1,248,00
Four Way Interaction			•		
Resource Price, Efficiency, Utilization, Parlent Mix (p.R.U.m.)	821.00	\$67.00	(\$5,75)	807.78	\$187.00
Total of Cost Variance Components **	\$81.028.00	\$203.605.00	(\$55 807.50)	. 82 67 817 78	2500 643 25









15/24

Figure 6A - Analysis of Overall Revenue and Profit Variances

Total Organization Dimension
Sales Revenue Variance Analysis

Revenue Congenitation Dimension

Revenue Variance Analysis

Revenue Congenitation Dimension

PCT Patent Submission - 2003-03-13
PCT Patent Submission - 2003-03-13
University of Ottawa

ABM-RCP Variance Analytics Model PCT Patent Stortistion - 2003-03-13 Colin M. Lay and Real Eden University of Others 2003-03-11 09:58 PM

ance Analytics Model Figure 5B n - 2003-03-13 fem	•Revenue and	Figure 5B • Revenue and Profit Variance Components for Products	Components for	Products	•		
			Pater	1 Types			L
DESE PM	Births - North	Birthe - CS	Cancer-Sone	Centrer - Lung	Cancer - Liver	Heart Disease	_
Product Dimension	DRG1	0802	EDNO	+080·	SDAG	DRGB	
Sales Revenue Variance Analysis	•						
Actual Total Revenue m Budgested Total Deserte	51,584,000,00 11,584,000,00	12.125.000.00 12.125.000.00	. \$500,000,00	1504,000,00 6472,000,00	1852,600,00 6474,000,00	#978,000,00	
Total Revenue Variance		\$325,000.00		(\$60,000,00)	•		
Saling Price Revenue Variance (sp) =	840,000,00	\$75,000,00	(trico	(\$37,500,00)	(\$22,500.00)	\$20,000,00	
Patent Mx Revenue Variance (m) a Sellino Price, Patent Mix Interaction Revenue Variance (so.m) a	\$140,000.00	\$10,000,00	80.00	(\$45,000,00)	00.03	(\$240,000,00)	

\$4,432,500,00 \$4,250,000,00 \$182,500,00

\$74,000,00 \$94,000,00 \$12,500,00 182,500,00

Note: Positive revenue and profit variances are favorable. Positive cost variances are untavorable

\$460,068.76 \$864,200.00 (\$364,143.25)

(\$12,934.00) \$159,000.00 (\$172,934.00)

\$41,396.50 \$82,700.00 (\$51,304.50)

(\$4.620.00) \$100,500.00 (\$100,120.00)

\$175,656.50 \$141,000,00 \$34,656.50

\$257, \$44,00 \$122,000,00 (\$64,655.00)

Profit Variance Analysis
Actus fow Profit
Budgesed fotst Profit
Total Profit Variance =

\$22,500.00]

\$80,000,003

325,000,00

184,600.00

Total of Revenue Variance Components

\$162,500,00 \$268,043,25]

(\$224,000.00) (\$31,068.00) (\$172,834.00)

(\$21,304.50)

(\$108,120.00)

\$2.00 \$21,688,25 (\$21,988,25)

\$22,000.00 \$20,143.60 \$34,858.50

\$184,000.00 \$248,655.00 (\$84,655,00)

Total Revenue Variance Total Cost Variance Total Profit Variance -

BM-RCP Variance Analytics Model F

•	
5	
ō	
7	
÷	
잍	
õ	
Ž.	
Ξ.	
<b>&gt;</b>	
ĸ	
22	
Ē	
2	
δ	
ڃ	
Ė	
ß	
~	
<u>o</u>	
5	
Ë	
Œ	
rigure oc - Kevenue and Front Variance Components for Product G	
Ę	
2	
7	
0	
•	
ž	
g	
Σ	
é	
•	
•	
ñ	
•	
5	
<u></u>	
Ľ	
5	
5	
5	
=	


74						
i.	Product-Group Dimension			- C- G	į	
Sale	Sales Revenue Variance Analysis					
	Achief Total Revenue m	\$2,700,000,00	\$1,747,800,00	\$978,000.00	\$4,412,500,00	
	Budgetod Total Revenue	\$3,200,000,00	\$1,850,000,00	\$1,200,000,00	\$4,250,000,00	
	Total Revenue Variance	\$509,000,00	(\$102,500,00)	(\$224,000,00)	\$162,500,00	
	Setting Price Revenue Variance (sp) =	\$115,000,00	(00'000'06\$)	\$20,000.00	\$73,000.00	
Setting Price, Patent M	Patent Wix Revenue Valence (m) = Revenue Valence (m) = Revenue Valence (m m) =	\$380,000,00	(\$45,000.00)	(\$240,000,00)	\$95,000,00	
. Tot	Total of Revenue Variance Components	\$\$	(\$102,500,00)	(\$224,000.00)	\$152,500,00	
	Profft Variance Analysis					
	Actual Total Profit		\$60,768.25	(\$13,934,00)	\$400,050,76	
	Total Profit Variance	(\$29,798.50)	(\$18), 410,75)	(\$172,934,00)	(554,14.25)	
	Total Revenue Varience -	\$509,000,00	(\$102,500.00)	(\$224,000.00)	\$162,500.00	
arbtact	Total Cost Variance	\$538,798.Bo	\$72,010.78	(\$51,066.00)	\$566,649,25	
	Total Profit Variance	(\$29,798,50)	(\$181,410,75)	(\$172.934.00)	(\$384 142.25)	


Note: Positive revenue and profit variances are favore


18/24

Figure 5D - Revenue, Profit and Cost Variance Graphs at the Level of Patient Type


ABM-RCP Variance Analytics Model
PCT Patent Submission - 2003-03-13
Colin M. Lay and Ron Eden
University of Ottawa
2003-03-11 09:13 PM


















19/24 SUBSTITUTE SHEET (RULE 26)

PCT/CA03/00352



20/24 SUBSTITUTE SHEET (RULE 26)

ABM-RCP Variance Analytics Model PCT Patent Submission - 2003-03-13
Colle M. Lay and Ron Eden

Figure 7 - Activity Managers Detailed Reports of the impact of Efficiency Changes

Colin M. Lay and Ron Edon University of Ottawa 2003-03-11 09:18 PM

Focus on Activity Efficiency Changes - Units of Resources Used per Unit of Service Matte R - Resources Used to Create 1 Unit of Each Service

		Hursing 1	Nursing 2	Lab Tech	X-Rays	Pharmacy	•
	Ra	A1	AZ	A3	A4	A5	Ru · Actual Values of Resources to Services (Activities) Transformat
Cabour 1	R1	1.11	DI	1,2	0.2	0.9	
Labour 2	82	0.5	1.9	8,8	1.5	1.7	
Supplies 1	83	2,5	1.5	3.6	4.1	4.5	
Supplies 2	R4[	4	0,0	1.5	5.2	2.8	
		Number 1	Nursing 2	Lab Tests	X-Rays	Pharmacy	
	Rb	A1	A2	A3	Å4	AS	Rb = Budgeted Values
Labour 1	R1[	.11		1	Q	1	
Labour 2	R2	9	2	1	1	. 2	
Supplies 1 -	83	2	2	3	. 4	5	
Supples 2	84	3	11		Б		
							• .
		Mustag 1	Mursing 2	Lab Tests	X-Rays	Pharmacy	•
	Rab_	A1	A2_	A9	M_	A5	Rati = Difference
Labour 1	RI	9.1	0	9,2	0.2	-0.1	P Actual - Budget
Labour 2	RZ	0.5	-0.1	-0,2	0.5	-0.3	Efficiency Charge
Supplies I	R3	0.5	-0.5	0.8	0.11	-0.5	• •
Supplies 2	R4_	1	-0.2	-0.5	0.2	-0.2	
		Number 1	Musky 2	Lab Tests	X-Rays	Phaneacy	
% D:	II Rab_	A1	A2		:M	· A5	% Oifforence
Labour 1	R1	10.0	0.01	20.0 10	tritte	-100	<ul> <li>Efficiency Change</li> </ul>
Labour 2	RZ In	firete	-5,0	-20.0	60.0	-15.0	• • •
Supplies 1	R3	25.0	-25.0	26.7	2.5	-10.0	
Supples 2	RA	33.5	-20.0	-25.0	4.0	4.7	

Focus on Activity Efficiency Changes Impact on Resources Used increase (Decrease) Resources Used Caused by Activity Efficiency Change everything cise (U, m) at Budget

		Nuning 1 A1	Norsing 2 A2	Lob Tests A3	X-Rays A4	Phannacy A5	Total
Labour 1	RI	700.01	6.61	2,210,0	4,140.0	-1,915,01	5,135.0
Labour 2	R2	3,500,0	-970,0	-2.210.0	10,350,0	-6.745.0	4,925.0
Supplies 1	RS	3,500.0	-4,850,0	8,640.0	2,070.0	-9,576.0	-15.0
Supplies 2	R4 □	7,000.0	-1,940,0	-5,525,0	4,140,0	-3,830.0	-155,0

### Increase (Decrease) Resources Used Caused by Activity Efficiency Change amending size fill miles Activity

		Nursing 1	Nursing 2	Lab Tests	X-Rays	Phermacy	Total
		A1	A2	A3	. M	A5	
Labour 1	R1	824.0	0.0	2,150.0	4,270.0	-2,058.0	5,186.0
Labour 2	RZ	4,120.0	-014.0	-2,150,0	10,675.0	-6,174.0	5,557.0
Supplies 1	R3	4,120,0	4,570.0	0.000,8	2,135,0	-10,290.0	-6,0
Supplies 2	R4	8,240.0	-1,828.0	-5,375.0	4,270.0	-4,116.C	1,191.0

#### Increase (Decrease) \$ for Resources Used Caused by Activity Efficiency Change

		Nursing 1	Nursing 2	Lab Tests	X-Rays	Pharmacy	Total
		A1	A2	. 43	A	AS.	
Labour 1	Rt[	\$9,000,00	\$0.00	\$30,940,00	\$57,980,00	-\$26,810.00	\$71,890.00
Labour 2	RZ	\$45,500.00	-\$12,610.00	-\$26,730.00	\$134,550,00	\$74,695.00	\$64,025.00
Supplies 1	ro F	\$31,500.00	-\$43,650.00	379,500.00	\$16,630.00	-\$80,175.00	-\$135,00
Supplies 2	R4	\$49,000,00	-\$13,580,00	-\$38,675.00	\$26,980.00	-\$26,810.00	-\$1,065.00
Total	_	\$135,800,00	-\$49,840,00	\$43,005,00	\$240,120,00	\$214,480.00	\$134,895,00

## Focus on Activity Efficiency Changes impact on Patient Groups Increase (Decrease) of Average Patient Group that Cost Caused by Activity Efficiency Change

		Nursing 1	Nursing 2	Lab Tests	X-Rays	Phamacy	Total
	-	A1	A2		A4		
Bittle - Norm	DRG1	\$19.40	\$0.00	\$0.00	\$21.20	\$33,60	\$9.00
Births - CS	DRG2	\$19.40	-47,20	\$7,80	840,40	-\$56,00	\$10.40
Cancer-Bone	DRG3	\$6,00	-\$14,40	\$3,90	\$56,00	-\$33,60	\$13.90
Cancer - Lung	DRG4	\$38.80	-\$14.40	\$3.90	\$73.20	-\$33.60	\$17.90
Cancer - Liver	DRG6	\$0.00	\$21.80	\$7.80	\$34.60	-\$11.20	\$9.60
Heart Olsease	DRG6	\$36.80	\$21.60	\$19.50	\$40,40	-\$11,20	\$71.90

#### Increase (Decrease) of Total \$ of Services Caused by Adhity Efficiency Charge

		Nursing 1	Nursing 2	Lab Tests	XRays	Pharmacy	Total
	_	<u>Ā</u> I	A2_	A3	A1	A\$	
Births - Horm	DRG1	\$38,600,00	\$0.00	\$0.00	\$46,400.00	\$87,200.00	\$18,000.00
Births - CS	DRG2	\$29,190.00	-\$10,600,00	\$11,700,00	\$69,600,00	-\$84,000,00	\$15,600,00
Cancer-Bone	DRG3	\$0.00	-17,200,00	\$1,950,00	\$29,000.00	-\$16,600.00	\$8,950.00
Cancer - Lung	DRG	\$29,100.00	-\$10,800,00	\$2,925.00	\$17,400.00	-\$25,200.00	\$13,425.00
Cencer - Liver	DRGS	\$0.00	-619,440.00	\$7,020.00	\$31,320,00	-\$10,000.00	\$8,620,00
Heart Disease	DRG6	\$38,800.00	\$21,800.00	19,300.00	\$46,400.00	-\$11,200.00	\$71,900.00
Total	_	\$135,800.00	\$69,840.00	\$43,095,00	\$240,120.00	-\$214,480.00	\$134,695,00


ABM-RCP Variance Analytics Model PCT Patent Submission - 2003-03-13 Colin M, Lay and Ros Eden University of Ottawa 2003-03-11 09:13 PM

Figure 8 - Product Managers Detailed Reports of the Impact of Utilization Changes

		Baths - Nome	Blieftes - CS	Caronr-Bone	Center - Lung	Carcer - Liver	Heart Disease	
	Ua	1070	DRGS	DRG3	DRG4	DRGS	DR06	Uz = Actual Values of Utiliz
Nursing 1	Ati	1,5	1.0	0.0	2.0	. 6.5	22)	- Treatment Protocot
Number 2	AS	0.0	0.0	2,0	2.0	2.5	3,7	
Lab Tests	A3	0.0	2.0	0,9	1.0	2.91	· \$.6	
X-Farys	M	. 2.0	4.0	6.0	2.6	3.0	3.0	
Pharmace	AS	3.0	5.0	3.0	3.0	121	1.0	


Focus on Utilization (Treatment Protocols) Changes - Average Activity Levels per Patient by Patient Group

	Ub	Births - Horma DRG1	Birthe - C3 DRG2		Cancer - Lung DRG4	Cascer - Liver DRGS	Hamil Disease DRGs
Nursing 1	AII	10	1.0	0.0	2.0	0.01	2.0
Number 2	A2	0.0	1.0	2.0	2,0	3.0	3.0
Lab Tests	ادم	9,0	2.0	1,0	1.0	2.0	5,0
X-Rays	M	2.0	4.0	5.0	2.0	3.0	4.0
Phantaly	A5	3,0	5,0	3.0	3.0	1,01	
			•				





% 08	TU2b	Skitus - Morro DRG1	Strons - C3 DRG2	Cancer-Bone DRG3	Carcer - Lung DRG4	Cancer - Liver ORGS	Heart Disease DRG6
Numbrg 1	A1	60,0	9,4	6.0	0.0	0.0	16.0
Numbro 2	AZ	0.0	• 55	0.0	0.0	-90,7	23,3
LibTat	ASI	0.0	0,0	-10.0	0.0	0.0	10.0
X-Rays	M	0.0	0.0	0.0	25,0	0.0	6.0
Plannacy	A5	0.0	0,0	0.0	9.0	20.0	6.0

Focus on Utilization (Treatment Protocols) Changes Impact on Resources Used



Focus on Utilization (Treatment Protocols) Changes Impact on Activities (Patient Services) Used





23/24 SUBSTITUTE SHEET (RULE 26)

١,٠

Resource Management Managerial Diagnostic Materials Management Figure 10 - Activity Based Management - Revenue, Cost, Profit Variances (Patent Application) Service Producing Patient Groups variances added -Selling price/ profit **Extensions** Departments **Departments ABM-RCP** - Activities - Personnel Tools Variance Components Variance Components 2-Way Interactions 3-Way Interactions 4-Way Interaction Total Hospital m - Patient Mix Total Variance R - Efficiency U - Utilization Main Effects Variance Analysis p - Price pRUm Total ∆p'RUm ∆RUm p'RUm **E**02 RUm E S \$ E ∆p'RU p'RU **₽** 2 B Differences Δp'R ρ'R 3 **Budgeted** ঠ ď

24/24
SUBSTITUTE SHEET (RULE 26)

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

□ BLACK BORDERS
□ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
□ FADED TEXT OR DRAWING
□ BLURRED OR ILLEGIBLE TEXT OR DRAWING
□ SKEWED/SLANTED IMAGES
□ COLOR OR BLACK AND WHITE PHOTOGRAPHS
□ CRAY SCALE DOCUMENTS
□ LINES OR MARKS ON ORIGINAL DOCUMENT
□ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

## IMAGES ARE BEST AVAILABLE COPY.

OTHER: \_\_\_

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.